^
    1m
    A Phase 2 Clinical Study of ABSK061 and ABSK043 (clinicaltrials.gov)
    P2, N=202, Recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR3 overexpression • FGF3 overexpression
    |
    ABSK043 • ABSK061
    2ms
    A Phase 2 Clinical Study of ABSK061 and ABSK043 (clinicaltrials.gov)
    P2, N=202, Not yet recruiting, Abbisko Therapeutics Co, Ltd
    New P2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR3 overexpression • FGF3 overexpression
    |
    ABSK043 • ABSK061
    over2years
    A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=85, Recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Jun 2022
    Enrollment open • Trial initiation date
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion
    |
    ABSK061
    almost3years
    A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=85, Not yet recruiting, Abbisko Therapeutics Co, Ltd
    New P1 trial
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion
    |
    ABSK061